516 related articles for article (PubMed ID: 30306859)
41. Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives.
Tsouka AN; Tellis CC; Tselepis AD
Curr Pharm Des; 2018; 24(31):3622-3633. PubMed ID: 30317986
[TBL] [Abstract][Full Text] [Related]
42. PCSK9 inhibition in the management of familial hypercholesterolemia.
Ogura M
J Cardiol; 2018 Jan; 71(1):1-7. PubMed ID: 28784313
[TBL] [Abstract][Full Text] [Related]
43. ANGPTL3 as therapeutic target.
Kersten S
Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
[TBL] [Abstract][Full Text] [Related]
44. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
Berman AN; Blankstein R
Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
[TBL] [Abstract][Full Text] [Related]
45. PCSK9 in cholesterol metabolism: from bench to bedside.
Reiss AB; Shah N; Muhieddine D; Zhen J; Yudkevich J; Kasselman LJ; DeLeon J
Clin Sci (Lond); 2018 Jun; 132(11):1135-1153. PubMed ID: 29895529
[TBL] [Abstract][Full Text] [Related]
46. New developments in atherosclerosis: clinical potential of PCSK9 inhibition.
Giunzioni I; Tavori H
Vasc Health Risk Manag; 2015; 11():493-501. PubMed ID: 26345307
[TBL] [Abstract][Full Text] [Related]
47. PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
El Khoury P; Elbitar S; Ghaleb Y; Khalil YA; Varret M; Boileau C; Abifadel M
Curr Atheroscler Rep; 2017 Oct; 19(12):49. PubMed ID: 29038906
[TBL] [Abstract][Full Text] [Related]
48. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
[TBL] [Abstract][Full Text] [Related]
49. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
50. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
51. PCSK9 inhibition and inflammation: A narrative review.
Ruscica M; Tokgözoğlu L; Corsini A; Sirtori CR
Atherosclerosis; 2019 Sep; 288():146-155. PubMed ID: 31404822
[TBL] [Abstract][Full Text] [Related]
52. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease.
Alkhalil M
Curr Drug Metab; 2019; 20(1):72-82. PubMed ID: 30112987
[TBL] [Abstract][Full Text] [Related]
53. Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects.
Lupo MG; Ferri N
J Cardiovasc Dev Dis; 2018 Jul; 5(3):. PubMed ID: 30011918
[TBL] [Abstract][Full Text] [Related]
54. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
Koskinas K; Wilhelm M; Windecker S
Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
[TBL] [Abstract][Full Text] [Related]
55. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
[TBL] [Abstract][Full Text] [Related]
56. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Hadjiphilippou S; Ray KK
Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304
[TBL] [Abstract][Full Text] [Related]
57. PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.
Raal FJ; Chilton R; Ranjith N; Rambiritch V; Leisegang RF; Ebrahim IO; Tonder AV; Shunmoogam N; Bouharati C; Musa MG; Karamchand S; Naidoo P; Blom DJ
Endocr Metab Immune Disord Drug Targets; 2020; 20(6):840-854. PubMed ID: 32053090
[TBL] [Abstract][Full Text] [Related]
58. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
Polychronopoulos G; Tziomalos K
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
[TBL] [Abstract][Full Text] [Related]
59. Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.
Ahangari N; Ghayour Mobarhan M; Sahebkar A; Pasdar A
Ann Med; 2018 Jun; 50(4):303-311. PubMed ID: 29578362
[TBL] [Abstract][Full Text] [Related]
60. PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease.
Delialis D; Dimopoulou MA; Papaioannou M; Kotsira G; Maneta E; Mavraganis G; Loutos C; Georgiopoulos G; Stamatelopoulos K
Curr Pharm Des; 2023; 29(23):1802-1824. PubMed ID: 37055909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]